30.08.2018
Biofrontera AG DE0006046113
DGAP-News: Biofrontera AG: Reminder - Biofrontera Announces Conference Call to Discuss Half Year 2018 Financial Results
DGAP-News: Biofrontera AG / Key word(s): Half Year Results
Biofrontera AG: Reminder - Biofrontera Announces Conference Call to Discuss
Half Year 2018 Financial Results
30.08.2018 / 11:35
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Reminder: Biofrontera Announces Conference Call to Discuss Half Year 2018
Financial Results
Leverkusen, Germany, August 30, 2018 - Biofrontera AG (NASDAQ: BFRA;
Frankfurt Stock Exchange: B8F) (the "Company"), an international
biopharmaceutical company, will be releasing its financial results for the
6-month period ended June 30th, 2018 on August 31st, 2018.
Conference calls for shareholders and interested investors will be held on
August 31st, 2018 at the following times:
In German, at 10:00 am CEST (4.00 am EDT)
Dial-in number Germany: +49 (0)69 2222 25204
Conference code: 3448423
In English, at 2:30 pm CEST (8.30 am EDT)
Dial-in number USA: +1 929 477 0402
Dial-in number UK: +44 (0)330 336 9411
Conference code: 5675352
Please dial in 5 minutes ahead of time to ensure a timely start of the
conference call.
-END-
For enquiries, please contact: +49 (0) 214 87 63 2 0
Biofrontera AG [email protected]
Thomas Schaffer, Chief Financial Officer
IR UK: Seton Services +44 (0) 207 224 8468
Toni Vallen
IR and PR US: The Ruth Group +1 646-536-7035
IR: Tram Bui +1 508-280-6592
PR: Kirsten Thomas
About Biofrontera:
Biofrontera AG is an international biopharmaceutical company specializing in
the development and commercialization of a platform of pharmaceutical
products for the treatment of dermatological conditions and diseases caused
primarily by exposure to sunlight that results in sun damage to the skin.
Biofrontera's approved products focus on the treatment in the U.S. and
Europe of actinic keratoses, which are skin lesions that can sometimes lead
to skin cancer, as well as the treatment of certain forms of basal cell
carcinoma in the European Union. American Depositary Shares representing
Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under
the symbol "BFRA", and Biofrontera's ordinary shares are listed in the
Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also
available at www.biofrontera.com.
Forward Looking Statements:
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 regarding
the public offering and the intended use of proceeds from the offering.
These statements may be identified by the use of forward-looking words such
as "anticipate," "believe," "forecast," "estimate" and "intend," among
others. Such forward-looking statements are based on the currently held
beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance, or
achievements of the Company, or industry results, to differ materially from
the results, financial condition, performance or achievements expressed or
implied by such forward-looking statements. These risks, uncertainties and
other factors are set forth in the Registration Statement on Form F-1 filed
with the SEC, including in the section "Risk Factors," and in future reports
filed with the SEC. Given these risks, uncertainties and other factors,
prospective investors are cautioned not to place undue reliance on these
forward-looking statements. The Company does not undertake an obligation to
update or revise any forward-looking statement.
---------------------------------------------------------------------------
30.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service
---------------------------------------------------------------------------
719095 30.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biofrontera AG ISIN: DE0006046113 können Sie bei EQS abrufen
Biotechnologie , 604611 , B8F , XETR:B8F